One A Day Marketing Claims Spark Another CSPI-Bayer Face Off
This article was originally published in The Tan Sheet
Executive Summary
The Center for Science in the Public Interest threatens to sue if Bayer HealthCare does not discontinue claims that One A Day multivitamins “support” breast, heart, eye and bone health. CSPI argues the problem is rooted in linking legitimate claims to scientific research in a way that implies disease claims.
You may also be interested in...
Bayer Says One A Day Selenium Prostate Cancer Claims Are In Fair Play
Bayer asserts the prostate cancer risk reduction claims for its One A Day Men's multivitamin supplements are backed by an FDA-approved qualified health claim for selenium
FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action
Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.